← Leaderboards
Anne Kathleen Radcliff
Cubrc, Inc.
$23,902,389
Attributed
$25,304,328
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $6.9M · FY2011–22$10M$7.5M$5M$2.5M$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$25,304,328 · 2
By mechanism
N01$22,500,450 · 1
R01$2,803,878 · 1
Top collaborators
- Trudy Hope Grossman4 shared
- Joyce A Sutcliffe1 shared
Others in their field
Top investigators on “Anti-Bacterial Agents”
- Richard H. Ebright · Rutgers The St Univ Of Nj New Brunswick$26,177,144
- Yat Sun Or · Enanta Pharmaceuticals, Inc.$23,534,108
- Bruce Blough · Research Triangle Institute$19,637,160
- Ramnik J Xavier · Broad Institute, Inc.$19,590,431
- David S Perlin · Hackensack University Medical Center$14,378,517
- Charles Testa · Echelon Biosciences, Inc.$13,103,850
Research focus
Anti-Bacterial AgentsBiodefensePre-ClinicalRespiratory Tract InfectionsTetracyclinesTranslational ResearchAdvanced DevelopmentResearch And DevelopmentProduct DevelopmentSupport ContractsPathogenAntimicrobial ResistanceDrug ResistanceLung DiseasesYersinia PestisFrancisella TularensisAutopsyAppearanceAmes AssayAntibioticsAftercareAdverse EffectsCellsCategories
Grant awards (16)
DEVELOPMENT OF NOVEL TETRACYCLINE COUNTERMEASURES FOR RESPIRATORY DISEASES$71,282
N01 · FY2022 · AI · contact PI
DEVELOPMENT OF NOVEL TETRACYCLINE COUNTERMEASURES FOR RESPIRATORY DISEASES$71,281
N01 · FY2022 · AI · contact PI
DEVELOPMENT OF NOVEL TETRACYCLINE COUNTERMEASURES FOR RESPIRATORY DISEASES$3,184,516
N01 · FY2016 · AI · contact PI
DEVELOPMENT OF NOVEL TETRACYCLINE COUNTERMEASURES FOR RESPIRATORY DISEASES$3,184,516
N01 · FY2016 · AI · contact PI
DEVELOPMENT OF NOVEL TETRACYCLINE COUNTERMEASURES FOR RESPIRATORY DISEASES$1,743,108
N01 · FY2015 · AI · contact PI
DEVELOPMENT OF NOVEL TETRACYCLINE COUNTERMEASURES FOR RESPIRATORY DISEASES$1,743,107
N01 · FY2015 · AI · contact PI
Development of TP-217 as a highly efficacious, broad-spectrum antibiotic for the$496,101
R01 · FY2015 · AI · contact PI
DEVELOPMENT OF NOVEL TETRACYCLINE COUNTERMEASURES FOR RESPIRATORY DISEASES$3,023,963
N01 · FY2014 · AI · contact PI
DEVELOPMENT OF NOVEL TETRACYCLINE COUNTERMEASURES FOR RESPIRATORY DISEASES$2,901,309
N01 · FY2014 · AI · contact PI
Development of TP-217 as a highly efficacious, broad-spectrum antibiotic for the$481,592
R01 · FY2014 · AI · contact PI
DEVELOPMENT OF NOVEL TETRACYCLINE COUNTERMEASURES FOR RESPIRATORY DISEASES$122,654
N01 · FY2014 · AI · contact PI
DEVELOPMENT OF NOVEL TETRACYCLINE COUNTERMEASURES FOR RESPIRATORY DISEASE$3,227,357
N01 · FY2013 · AI · contact PI
DEVELOPMENT OF NOVEL COUNTERMEASURES FOR RESPIRATORY DISEASES$3,227,357
N01 · FY2013 · AI · contact PI
Development of TP-217 as a highly efficacious, broad-spectrum antibiotic for the$476,117
R01 · FY2013 · AI · contact PI
Development of TP-217 as a highly efficacious, broad-spectrum antibiotic for the$521,128
R01 · FY2012 · AI · contact PI
Development of TP-217 as a highly efficacious, broad-spectrum antibiotic for the$828,940
R01 · FY2011 · AI · contact PI